Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nyse  >  Baxter International    BAX

BAXTER INTERNATIONAL (BAX)
Mes dernières consult.
Most popular
  Report  
SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsSector newsTweets

Baxter International Inc. : Baxter's Investigational Hemophilia Treatment Yields Positive Results

share with twitter share with LinkedIn share with facebook
share via e-mail
0
12/10/2012 | 03:34pm CET
    By Saabira Chaudhuri 
 

Baxter International Inc. (BAX) said results from a study evaluating its investigational treatment for patients with hemophilia B were positive.

The medical product company's BAX 326--its investigational recombinant factor IX protein for the treatment and prophylaxis of bleeding episodes for patients with hemophilia B over 12 years of age--was recently granted orphan-drug designation by the U.S. Food and Drug Administration.

"With only one recombinant protein currently available to treat hemophilia B, it was important to focus research efforts on finding another option for patients with this debilitating disease," Lead Investigator Jerzy Windyga said. "In this study, more than 40 percent of patients using BAX 326 as a prophylactic treatment experienced no bleeds, an important finding given the potentially harmful impact of bleeding episodes for patients."

The study investigated the efficacy and safety of BAX 326 in 73 previously treated patients with severe or moderately severe hemophilia B.

Baxter noted that hemophilia B is the second most common type of hemophilia--also known as Christmas disease--and is the result of insufficient amounts of clotting factor IX, a naturally occurring protein in blood that controls bleeding. The company added that about 25,000 people world-wide, including more than 4,000 in the U.S., have been diagnosed with hemophilia B.

Baxter's profits have improved for more than a year on strong demand for its hemophilia and immunodeficiency products. Its bottom line has been less pressured by the slowdown in health-care spending, compared with some peers, because Baxter focuses on medical devices and pharmaceuticals used to treat life-threatening ailments and injuries.

In October, Baxter said its third-quarter earnings rose 1.2% as the company's margins improved, though sales were short of its prior guidance.

Shares closed Friday at $65.07 and were inactive in recent premarket trading. The stock has risen 32% so far this year.

Write to Saabira Chaudhuri at [email protected]

Subscribe to WSJ: http://online.wsj.com?mod=djnwires

Stocks mentioned in the article
ChangeLast1st jan.
BAXTER INTERNATIONAL 1.38% 68.36 Delayed Quote.4.32%
share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on BAXTER INTERNATIONAL
02/23BAXTER INTERNATIONAL INC : Change in Directors or Principal Officers (form 8-K)
AQ
02/23BAXTER INTERNATIONAL : to Present at the Barclays Global Healthcare Conference
AQ
02/23BAXTER INTERNATIONAL : Management's Discussion and Analysis of Financial Conditi..
AQ
02/22BAXTER INTERNATIONAL : Hospitals Grapple with National IV Bag Shortage
AQ
02/20BAXTER INTERNATIONAL : Declares Quarterly Dividend and Announces Expanded Share ..
BU
02/15BAXTER INTERNATIONAL : U.S. Patents Awarded to Inventors in Florida (Feb. 15)
AQ
02/15BAXTER INTERNATIONAL : to Present at the Raymond James & Associates 39th Annual ..
AQ
02/12BAXTER INTERNATIONAL : New Drug Delivery Technologies Extending to Even Aspirin
AQ
02/08BAXTER INTERNATIONAL : Klingenstein Fields & Co. LLC Sells 1,370 Shares of Baxte..
AQ
02/07BAXTER INTERNATIONAL : Reports 2017 Fourth-Quarter and Full-Year Results
AQ
More news
News from SeekingAlpha
02/22Tracking Dan Loeb's Third Point Portfolio - Q4 2017 Update 
02/21Tracking Tweedy Browne Portfolio - Q4 2017 Update 
02/20Baxter declares $0.16 dividend 
02/20Premarket analyst action - healthcare 
02/09Merger Arbitrage Opportunity In NxStage Medical - $30 Cash Offer From Freseni.. 
Financials ($)
Sales 2018 11 242 M
EBIT 2018 1 910 M
Net income 2018 1 437 M
Finance 2018 664 M
Yield 2018 1,02%
P/E ratio 2018 26,73
P/E ratio 2019 22,79
EV / Sales 2018 3,19x
EV / Sales 2019 2,97x
Capitalization 36 531 M
Chart BAXTER INTERNATIONAL
Duration : Period :
Baxter International Technical Analysis Chart | BAX | US0718131099 | 4-Traders
Technical analysis trends BAXTER INTERNATIONAL
Short TermMid-TermLong Term
TrendsNeutralNeutralBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 18
Average target price 75,6 $
Spread / Average Target 13%
EPS Revisions
Managers
NameTitle
José E. Almeida Chairman, President & Chief Executive Officer
Scott Pleau Vice President-Operations
James K. Saccaro Chief Financial Officer & Vice President
Paul E. Martin Chief Information Officer & Vice President
John D. Forsyth Independent Director
Sector and Competitors
1st jan.Capitalization (M$)
BAXTER INTERNATIONAL4.32%36 531
MEDTRONIC PLC-0.42%109 254
ZIMMER BIOMET HOLDINGS-2.56%24 030
ALIGN TECHNOLOGY16.87%20 216
HOYA CORPORATION-6.17%19 502
TERUMO CORP1.67%19 406